1132-17-8

Basic information

• Product Name: 4-ETHOXY-BENZENESULFONYL CHLORIDE
• Synonyms: 4-ethoxybenzenesulfonyl chloride(SALTDATA: FREE);Benzenesulfonyl chloride, 4-ethoxy-;4-Ethoxybenzene-1-sulfonyl chloride
• CAS NO: 1132-17-8
• Molecular Formula: C₈H₉ClO₃S
• Molecular Weight: 220.68
• Mol File: 1132-17-8.mol
• Article Data: 10

Chemical Properties

• Boiling Point: 327.9°C at 760 mmHg
• Flash Point: 152.1°C
• Appearance: /
• Density: 1.324g/cm³
• Vapor Pressure: 0.000375mmHg at 25°C
• Refractive Index: 1.529
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 4-ETHOXY-BENZENESULFONYL CHLORIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-ETHOXY-BENZENESULFONYL CHLORIDE(1132-17-8)
• EPA Substance Registry System: 4-ETHOXY-BENZENESULFONYL CHLORIDE(1132-17-8)

Safety Data

• RIDADR: UN 3261 8 / PGIII
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 1132-17-8(Hazardous Substances Data)

Usage

General Description

4-ETHOXY-BENZENESULFONYL CHLORIDE, also known as ethyl 4-chlorobenzenesulfonate, is a chemical compound with the molecular formula C8H9ClO3S. It is a clear, colorless to slightly yellow liquid with a pungent odor, commonly used as an intermediate in the production of pharmaceuticals and other organic compounds. 4-ETHOXY-BENZENESULFONYL CHLORIDE is a sulfonyl chloride, which means it contains a sulfur atom bound to two oxygen atoms and a chlorine atom, and the ethoxy group is attached to the benzene ring. 4-ETHOXY-BENZENESULFONYL CHLORIDE is highly reactive and must be handled with caution due to its corrosive and toxic properties. It is commonly used in the synthesis of other chemicals and is an important building block in organic chemistry.

InChI:InChI=1/C8H9ClO3S/c1-2-12-7-3-5-8(6-4-7)13(9,10)11/h3-6H,2H2,1H3

Upstream product

• 103-73-1 Phenetole 
• 46204-52-8 4-ethoxybenzene-1-sulfonic acid 
• 825-90-1 sodium p-hydroxybenzenesulfonate 
• 7790-94-5 chlorosulfonic acid 
• 108-95-2 phenol 

Downstream Products

• 24924-80-9 4-ethoxyphenylsulfonyl hydrazide 
• 1132-19-0 4-ethoxybenzenesulfonamide 
• 333310-92-2 N-(4-chloro-phenyl)-4-ethoxy-benzenesulfonamide 
• 871827-53-1 methyl 3-{[(4-ethoxyphenyl)sulfonyl]-4-methylanilino}propanoate 
• 1191070-32-2 4-ethoxy-2-fluoro-N-(pyridin-2-ylmethyl)benzenesulfonamide 
• 415963-08-5 4-Ethoxy-N-[2-((2E)-2-{2-[hydroxy(oxido)amino]benzylidene}hydrazino)-2-oxoethyl]-N-(4-methylphenyl)benzenesulfonamide 
• 128887-34-3 1-(4-Ethoxy-3-nitro-benzenesulfonyl)-5-fluoro-1H-pyrimidine-2,4-dione 
• 70931-66-7 2-Ethoxy-7-fluoro-11-(4-methylpiperazino)-10,11-dihydrodibenzothiepin 
• 70931-68-9 <2-(4-Ethoxyphenylthio)-4-fluorophenyl>acetic Acid 

Relevant articles and documents

A practical synthesis of the dual matrix metalloprotease/tumor necrosis factor inhibitor MMP090

A practical 9-step synthesis of the dual matrix metalloprotease/ tumor necrosis factor inhibitor MMP090, trans-(R)-[[N-(4-ethoxyphenylsulfonyl)-N-(4- pyridinylmethyl)]amino]-N-hydroxy-4-propoxy cyclohexaneacetamide 10, was accomplished in 12% overall yield from D-4-hydroxyphenylglycine. Highlights include: (1) selective hydrogenation of D-hydroxyphenylglycine to afford predominantly the trans isomer without racemization; (2) virtually complete removal of the undesired cis diastereoisomer by fractional recrystallization of a TBS ether derivative of the functionalized cyclohexylglycine; (3) direct conversion of the TBS ether into the n-propyl ether in the presence of a catalytic amount of bismuth bromide in high yield; and (4) conversion of the carboxylic acid into the hydroxamic acid using an aqueous solution of hydroxylamine.

N-ARYL SULFONAMIDE DERIVATIVES AS VACCINE ADJUVANT

Bis-aryl sulfonamide compounds and methods of using those compounds, e.g., in a method of enhancing or prolonging an immune response, are provided. For example, the compounds may be employed with a vaccine and optionally at least one other adjuvant and/or one or more TLR ligands, at least one MAP kinase inhibitor, or any combination thereof.

Piperazine adenosine monophosphate activated protein kinase (AMPK) agonist and medical application thereof

The invention discloses a piperazine compound with AMPK agonist activity, and a preparation method and medical application of the piperazine compound. The piperazine compound is a compound shown as aformula (I) (please see the specifications for the formula), and a pharmaceutically acceptable salt or ester or a prodrug or N-oxide or solvate thereof. The compound can be used for preparing drugs for preventing or treating AMPK-mediated diseases.